ADA	anti-drug antibodies
ADC	antibody-drug conjugate
ADCC	antibody-dependent cell-mediated cytotoxicity
ALL	acute lymphoblastic leukemia
AML	acute myeloid leukemia
AUC	area under the curve
BBB	blood-brain barrier
BSA	body surface area
CDC	complement-dependent cytotoxicity
CMA	carrier-mediated agent
CL	clearance
DAR	drug–antibody ratio
DDI	drug–drug interaction
DM1	mertansine
DM4	ravtansine
ESRD	end stage renal disease
Fabs	Fab fragments
FcγR	Fc-gamma receptors
FcRn	neonatal Fc receptor
HGF	hepatocyte growth factor
iv	intravenously
KO	knockout
mAb	monoclonal antibody
MMAE	monomethyl auristatin E
MMAF	monomethyl auristatin F
MPS	mononuclear phagocyte system
NHP	non-human primate
NSCLC	non-small cell lung cancer
NP	nanoparticle
PD	pharmacodynamic
PDX	patient-derived xenografts
PEG	polyethylene glycol
PFS	progression-free survival
pI	isoelectric point
PK	pharmacokinetic
SABV	“sex as a biologic variable”
sc	subcutaneously
scFv	single chain variable fragment
TAM	tumor-associated macrophage
WT	wild type